Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy-Reference-Cited by-同舟云学术

Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

Published:2015-12-08 Issue:1 Volume:65 Page:73-82
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Liu Li,Zhao Guochao,Wu Wenchuan,Rong Yefei,Jin Dayong,Wang Dansong,Lou Wenhui,Qin Xinyu

Funder

the National Natural Science Foundation of China

the Science and Technology Commission of Shanghai Municipality

the Public Welfare Industry of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-015-1775-4.pdf

Reference41 articles.

1. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi: 10.3322/caac.21254

2. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579

3. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Sasaki H, Sueda T (2013) Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 71(2):419–429. doi: 10.1007/s00280-012-2029-1

4. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26(21):3503–3510. doi: 10.1200/JCO.2007.15.8469

5. Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital—Mayo Clinic collaborative study. Ann Surg Oncol 17(4):981–990. doi: 10.1245/s10434-009-0743-7

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Noncoding Ribonucleic Acids (RNAs) May Improve Response to Immunotherapy in Pancreatic Cancer;ACS Pharmacology & Translational Science;2024-08-07

2. Self‐Assembly of Biocompatible Core‐Shell Nanocapsules with Tunable Surface Functionality by Microfluidics for Enhanced Drug Delivery;Advanced Functional Materials;2024-08-02

3. FGFR2 fusion/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma;The Oncologist;2024-07-10

4. The causal effects of immune cells on pancreatic cancer: A 2‑sample Mendelian randomization study;Medicine;2024-04-19

5. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma;Frontiers in Immunology;2024-04-02